Use of Tocilizumab May Avoid the Need of Invasive Ventilation

Coronavirus disease 2019 (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Increased pro-inflammatory cytokines including interleukin 6 (IL-6) are associated with severe forms of illnesses. The severe cases of COVID-19 require a high amount of oxygen su...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikari, Anurag, Poudel, Ayusha, Pandey, Oshna, Aryal, Barun B, Dhungana, Bibek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500242/
https://www.ncbi.nlm.nih.gov/pubmed/34660032
http://dx.doi.org/10.7759/cureus.17822
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Increased pro-inflammatory cytokines including interleukin 6 (IL-6) are associated with severe forms of illnesses. The severe cases of COVID-19 require a high amount of oxygen supplementation and might even require endotracheal intubation with ventilator support. A blockade of inflammatory cascade with the use of tocilizumab has been shown to decrease the need for intubation and ventilator requirement.

Ejemplares similares